|
Match
|
Document |
Document Title |
|
|
6174996 |
Hybrid interferon τ/type I interferon polypeptides
The invention provides fusion proteins comprising an N-terminal region derived from an interferon-tau (IFN-τ) polypeptide and a C-terminal region derived from another type I interferon...
|
|
|
6156789 |
Method for treating abnormal cell proliferation in the brain
This invention relates to a method for treating abnormal cell proliferation in the brain by administering a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof:...
|
|
|
6156302 |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic...
|
|
|
6143292 |
Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
A method of treating a human cancer patient having a solid tumor comprising malignant cells is disclosed, wherein the patient having undergone a cancer therapy regimen comprising allogeneic stem...
|
|
|
6117423 |
Highly purified species of human leukocyte interferon
Disclosed is purified human leukocyte interferon, including human leukocyte interferon obtained from Namalva cells ("Namalva interferon") which, for the first time, is shown to contain a mixture of...
|
|
|
6096301 |
Combined interferon/antiestrogen therapy for treatment of breast cancer
Proliferation of breast cancer is treated by a combined type I interferon/non-steroidal antiestrogen therapy. Preferably antiestrogen treatment is sequential to treatment with interferon.
|
|
|
6086865 |
Methods of treating angiogenesis-induced diseases and pharmaceutical compositions thereof
The present invention provides for the use of fumagillin or an O-substituted fumagillol derivative in conjunction with interferon which increases the angiogenic inhibitory action as compared with...
|
|
|
6063373 |
Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
An improved method for the prevention of the inactivation of natural killer (NK) cells and the enhanced activation of NK cells in the presence of monocytes using a combination of a natural killer...
|
|
|
6042822 |
Interferon polymer conjugates
Compositions containing alpha interferon conjugated to a substantially non-antigenic polymer are disclosed in which at least about 30% of the conjugates include covalent attachment of the alpha...
|
|
|
6036949 |
Treatment of fibromyalgia with low doses of interferon
A method is described for using interferon in the treatment of human patients afflicted with fibromyalgia to alleviate one or more symptoms associated with that disease state. Fibromyalgia positive...
|
|
|
6020465 |
Recombinant avian type i interferon
The present invention relates to a chicken interferon gene coding for the amino acid sequence of SEQ ID NO: 2. The present invention also relates to a method of producing chicken interferon...
|
|
|
6013253 |
Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con in combination...
|
|
|
6007805 |
Use of interferon subtype alpha-8 (IFN-α.sub.8) to treat viral infections of the liver
Individual subtypes of interferon-α (IFN-α) have been found to have different antiviral activity in different cell types and are therefore used to prevent or treat viral infections in cell types...
|
|
|
6004549 |
Crystalline protein controlled release compositions
A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.
|
|
|
5997858 |
Stimulation of host defense mechanisms against tumors
A method for treating neoplastic disease in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon...
|
|
|
5993851 |
Method for preparing biphasic multilamellar lipid vesicles
A biphasic multilamellar lipid vesicle comprising a plurality of spaced apart lipid bilayers that include a liposome-forming component and optionally a biologically active agent entrapped within...
|
|
|
5989839 |
Use of MOLT4 CD69 expression to determine the presence and activity of interferon inhibitors
Disclosed is a method of determining the presence and activity of interferon inhibitors in a test sample, preferably human blood serum. The method includes the steps of culturing cells which...
|
|
|
5985263 |
Substantially pure histidine-linked protein polymer conjugates
Substantially pure histidine-linked protein-polymer conjugates and processes for their preparation are disclosed. The processes include contacting a protein with an activated polymer under...
|
|
|
5981493 |
Method of treating humans infected with human immunodeficiency virus
A method of treating an individual who is suffering from human immunodeficiency virus infection is disclosed. The method comprises administering to a human who is suffering from human...
|
|
|
5980884 |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous...
|
|
|
5972331 |
Crystalline interferon alpha for pulmonary delivery and method for producing the same
A method to prepare crystalline interferon alpha suitable for aerosol formulation either for systemic or topical (inhaled) drug delivery. The bioavailable interferon is in the form of crystalline...
|
|
|
5942224 |
Therapeutic agent for cat respiratory diseases and method of treatment using the same
A method using a therapeutic agent for cat respiratory diseases which contains a human interferon as an effective ingredient. The therapeutic agent exerts a strong efficacy on cats with only a...
|
|
|
5939286 |
Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
The present invention describes hybrid interferon fusion polypeptides formed of a first segment that contains the N-terminal amino acid sequence of an interferon-tau polypeptide, and a second...
|
|
|
5935566 |
Stable aqueous alfa interferon solution formulations
Stable aqueous solution formulations containing alfa-interferon type interferon, e.g., interferon alfa-2a and interferon alfa-2b, a buffer to maintain the pH in the range of 4.5-7.1, polysorbate 80...
|
|
|
5928639 |
Immunotherapy of cancer with allogeneic lymphocytes
Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant...
|
|
|
5928636 |
Use of IL-12 and IFNα for the treatment of infectious diseases
The present invention provides a combination of IL-12 and IFNα together with a pharmaceutically acceptable carrier useful for treatment and prophylaxis of infectious diseases, preferably chronic...
|
|
|
5910304 |
Low-dose oral administration of interferons
Improved methods for administering an interferon (IFN) to a warm-blooded vertebrate are described. The methods employ oral administration of the IFN to the vertebrate in very low dosages, for...
|
|
|
5885567 |
Treatment of infection in fowl by oral administration of avian interferon proteins
The present invention relates to a chicken interferon gene coding for the amino acid sequence of SEQ ID NO: 1. The present invention also relates to a method of producing biologically active...
|
|
|
5882640 |
Treatment of hyperallergenic response with oral interferon
Hyperallergenic conditions are treated by the administration of interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral...
|
|
|
5866115 |
Process for preparing dendritic cells, cells thus produced and containers for carrying out this process
Dendritic cells are of interest therapeutically as antigen-presenting cells. A process is disclosed in which peripheral blood cells are first isolated and the CD 34 antigen-expressing blood...
|
|
|
5863530 |
Treating ophthalmic fibrosis using interferon-α
The present invention relates to the use of topical interferon-α for the treatment of various forms of fibrosis in and around the eye arising from various ophthalmic diseases and procedures....
|
|
|
5858690 |
Method for detecting allergy
The present invention comprises a simple way of identifying the tendency towards allergy or allergy already broken out, and showing the probability of allergy in a patient, by measuring the...
|
|
|
5846526 |
Treatment of autoimmune disorders with oral interferon
Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in...
|
|
|
5830456 |
Treatment of viral disease with oral interferon-α
Viral infections are treated by the administration of alpha-interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and...
|
|
|
5830455 |
Method of treatment using a therapeutic combination of α interferon and free radical scavengers
The present invention relates to a therapeutic combination therapy involving the use of human interferon. The therapy involves the treatment of conditions susceptible to treatment with human...
|
|
|
5831023 |
Recombinant animal interferon polypeptides
Distinct α-, β- and γ-interferon genes from various animal species have been identified, cloned and expressed to produce the corresponding non-human animal interferon proteins. Specifically...
|
|
|
5824300 |
Treatment of neoplastic disease with oral interferon
Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with...
|
|
|
5817307 |
Treatment of bacterial infection with oral interferon-α
Bacterial infections are treated by the administration of alpha-interferon at a dosage of from about 0.1 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral...
|
|
|
5804557 |
Excipient stabilization of polypeptides treated with organic solvents
Methods and compositions for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with a polyol having a molecular...
|
|
|
5780021 |
Method for treating type 1 diabetes using α-interferon and/or β- i
A method is provided for preventing or treating an autoimmune disorder and/or recurrent autoimmune disorder in a transplant tissue in a mammal, which entails administering an effective amount of a...
|
|
|
5762923 |
Stabilized interferon alpha solutions
An aqueous interferon composition which comprises an amount of interferon-alpha dissolved in water with a non-ionic detergent and benzyl alcohol in amounts sufficient to stabilize the amount of...
|
|
|
5741485 |
Method for preparing zinc interferon alpha-2 crystals
A method for making crystals of zinc interferon alpha-2, and the use thereof in depot formulations, are disclosed.
|
|
|
5738846 |
Interferon polymer conjugates and process for preparing the same
Interferon-polymer conjugate containing compositions having high levels of retained interferon activity and relatively long circulating lives in vivo are disclosed. The compositions contain a...
|
|
|
5730971 |
Potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator
A potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator are provided. The potentiator is a mixture of flavin adenine dinucleotide...
|
|
|
5728378 |
Preparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin, amines or substances with corresponding receptor activity
Pharmaceutical preparation or system for activation of natural killer cells (NK cells), for example in order to treat tumors or virus infections, and which comprises a first composition containing...
|
|
|
5728707 |
Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
Methods and compositions for the prevention and/or inhibition of primary and secondary metastatic neoplasms are described. Individuals at a high risk of developing neoplasia and/or cancer patients...
|
|
|
5725852 |
Transmucosal therapeutic composition
A transmucosal therapeutic composition comprising a physiologically active peptide or protein and a cytidine nucleotide derivative was produced. The above composition results in a satisfactory...
|
|
|
5676942 |
Composition containing human alpha interferon species proteins and method for use thereof
This invention provides alpha interferon compositions comprising one or a mixture of selected highly antiviral interferon proteins, which compositions are characterized by increased anti-viral...
|
|
|
5632984 |
Method of treatment of macular degeneration
Intraocular administration of drugs such as α-2a interferon is employed in the treatment of age-related macular degeneration. Intraocular administration obviates the side effects associated with...
|
|
|
5628993 |
Sustained releasable parenteral pharmaceutical preparations and method of producing the same
A parenteral pharmaceutical preparation comprises a matrix containing a physiologically active peptide or protein and a polyglycerol diester of a saturated fatty acid, and the matrix is in a solid...
|